nrc.nl
Amsterdam Surpasses European Cities in Cannabis and MDMA Use
Amsterdam surpasses all European cities in cannabis and MDMA use in 2024, showing a 60% increase in cannabis and double the MDMA levels of other cities, according to a new report by the European Drug Agency based on wastewater analysis from 128 European cities in 26 countries.
- What are the potential long-term implications of Amsterdam's elevated drug use for public health, law enforcement, and social welfare?
- The study's findings suggest a need for further investigation into the factors driving Amsterdam's unique increase in drug use. The inconsistent year-to-year MDMA usage, compared to consistent daily cannabis use, warrants more research. The high, weekday ketamine use in Amsterdam is another notable area requiring future study to fully understand usage patterns and trends.
- How do Amsterdam's drug use trends compare to those of other major European cities, and what broader societal factors might explain these differences?
- The European Drug Agency's (EUDA) report contrasts Amsterdam's substantial rise in drug consumption with a general European decline in cannabis use. Amsterdam's cannabis levels were 60 percent higher in 2024 than 2023, while MDMA concentrations were double those of the next highest cities. This contrasts with the overall European trend of increasing stimulant use.
- What factors contribute to Amsterdam's unprecedented rise in cannabis and MDMA consumption compared to other European cities and to its own levels in 2023?
- Amsterdam's wastewater analysis reveals a significant surge in cannabis and MDMA use in 2024, exceeding other European cities, while Rotterdam saw a decrease. Amsterdam also leads in ketamine use, followed by Eindhoven. These findings, based on a week-long sampling of wastewater from 128 European cities, highlight Amsterdam's dramatic increase in drug use compared to 2023.
Cognitive Concepts
Framing Bias
The headline and introduction emphasize Amsterdam's rise as a European leader in drug use, potentially shaping reader perception towards a focus on Amsterdam rather than a broader European context. The article also highlights the increase in Amsterdam's cannabis use prominently, but mentions the overall decrease in cannabis use in Europe only later.
Language Bias
The language used is largely neutral, but phrases like "steekt met kop en schouders boven de andere steden uit" (stands head and shoulders above other cities) are slightly hyperbolic and could be toned down for greater objectivity. The article also describes the increase in drug use as 'flink' (considerably). While this isn't inherently biased, a more precise quantifiable description would enhance neutrality.
Bias by Omission
The article focuses primarily on Amsterdam's drug use increase, potentially omitting detailed analysis of other cities' trends or broader societal factors influencing drug use.
False Dichotomy
The article doesn't present a false dichotomy, but it could benefit from exploring the complexities behind the observed drug use patterns in different cities.
Sustainable Development Goals
The article reports a significant increase in cannabis and MDMA use in Amsterdam, exceeding other European cities. This rise in drug use directly impacts public health, increasing the risk of addiction, overdose, and related health problems. The mention of increased ketamine use further underscores the negative impact on the health and well-being of the population.